<h1>Remedium Lifecare Secures 182 Crore UK Contract for APIs, Set to Double Stock Prices and Boost Growth.</h1> Remedium Lifecare Limited has secured a significant multi-year contract worth 182 crore with a UK-based pharmaceutical distributor for supplying APIs, Intermediates, and Specialty Chemicals. This deal is expected to double the company's stock prices, marking a pivotal moment in India's pharmaceutical sector. With a PE ratio of 11, zero debt, and 65% promoter holding, Remedium is poised for substantial growth. The company's strategic expansion into API manufacturing, supported by advanced facilities in Hyderabad, enhances its global supply chain presence. Investors are advised to consider regulatory compliance and conduct thorough research before investing, despite the promising outlook.